21 reports

  • 4.1 ETIOLOGY AND PATHOPHYSIOLOGY

GlobalData epidemiologists calculated the age-standardized one-year total prevalence by multiplying the age-specific one-year total prevalence proportions from each country by the age-specific world standard population weights (Segi, 1960).

  • Opioid
  • Therapy
  • United States
  • Forecast
  • Omeros Corporation

(USA) ##.

  • Analgesic
  • Opioid
  • Therapy
  • United States
  • Market Shares

FOR ALL OTHER PARAMETERS, BOTH BATTERY CONTAINING AND BATTERY FREE [Light Therapy = ##]; [Others=##]; [Weight = ##] Score = [## = ##]; [## = ##. ##]; [## = ##]; [## < = ##]; [Weight = ##. ##] Score = [## - ## = ##]; [##-## = ##. ##]; [## - ##= ##.

  • Opioid
  • North America
  • United States
  • Eli Lilly & Co.
  • Grunenthal GmbH
  • NEO-1940 - DRUG PROFILE

The new dronabinol chewing gum product will be bioequivalent to Marinol, and will be used to help treat patients with chemotherapy induced nausea and vomiting and AIDS patients experiencing appetite and weight loss.

  • Chemotherapy
  • Opioid
  • United States
  • Product Initiative
  • Helsinn Group
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Clinical Trial
  • Eating Disorder
  • Hormone
  • Neurology
  • Opioid
  • INSYS THERAPEUTICS INC, PHOENIX, AZ COMPANY OVERVIEW

THIS DRUG IS APPROVED BY THE FDA APPROVED FOR TWO INDICATIONS: ##) CHEMOTHERAPY--INDUCED NAUSEA AND VOMITING (CINV); AND ##) ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH THE ACQUIRED IMMUNODEFICIENCY SYNDROME.

  • Opioid
  • Actavis plc
  • Bedrocan Canada Inc.
  • Insys Therapeutics, Inc.
  • Medical Marijuana, Inc.

One of the first patients who enrolled in the program reported a weight loss of ## pounds after three months along with healthier lifestyle habits.

  • Healthcare
  • Opioid
  • Therapy
  • United States
  • Biocorrx Inc
  • FAB'ENTECH SA
  • naloxone

Its lead product candidate, Syndros (dronabinol oral solution), is intended for the treatment of chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in AIDS patients.

  • Anesthetics
  • Opioid
  • United States
  • Product Initiative
  • Opiant Pharmaceuticals, Inc.
  • SUBSYS®

Anesthesia comprises of three main aspects, the pain relief or analgesia effect, loss of memory of the surgery, and the last one is the muscle relaxation to facilitate surgery and manipulation.

  • Opioid
  • North America
  • United States
  • World
  • Market Size
  • Clinical Trial Profile Snapshots

The prominent features of this report are - ##.

  • Clinical Trial
  • Eating Disorder
  • Mental Health
  • Neurology
  • Opioid
  • INDIVIOR PLC
  • OPIUM (OPIOID) ADDICTION - PIPELINE BY FAB'ENTECH SA, H2 2018

Its lead product candidate, Syndros (dronabinol oral solution), is intended for the treatment of chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in AIDS patients.

  • Opioid
  • Therapy
  • United States
  • Product Initiative
  • Addex Therapeutics Ltd
  • DRUG OVERDOSE - PIPELINE BY ICURE PHARMACEUTICAL INC, H1 2018
  • DRUG OVERDOSE - PIPELINE BY FAB'ENTECH SA, H1 2018

Its lead product candidate Syndros (dronabinol oral solution) is intended for the treatment of chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in patients with AIDS.

  • Opioid
  • Pharmaceutical
  • United States
  • Product Initiative
  • Opiant Pharmaceuticals, Inc.

Partner IntelGenx Corp, is developing this product in the USA under the accelerated ##(b)(##) pathway for chemotherapy-induced nausea and vomiting and anorexia and weight loss in people with AIDS (the same indications that have already been approved for Marinol).

  • Analgesic
  • Opioid
  • Canada
  • United States
  • Product Initiative
  • OPIUM (OPIOID) ADDICTION - PIPELINE BY INDIVIOR PLC, H1 2018
  • INSYS THERAPEUTICS INC

Its lead product candidate Syndros (dronabinol oral solution) is intendedfor the treatment of chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in patients with AIDS.

  • Opioid
  • Therapy
  • United States
  • Product Initiative
  • Addex Therapeutics Ltd
  • POST-OPERATIVE PAIN - PIPELINE BY INNOCOLL AG, H2 2018

Its lead product candidate, Syndros (dronabinol oral solution), is intended for the treatment of chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in AIDS patients.

  • Opioid
  • United States
  • Company
  • Product Initiative
  • AcelRx Pharmaceuticals, Inc.
  • 3. GDCT ID is the unique ID of GlobalData's Pharma Intelligence Center clinical trial database

The prominent features of this report are - ##.

  • Chronic Pain
  • Clinical Trial
  • Opioid
  • World
  • Pain Therapeutics
  • CANCER PAIN - PIPELINE BY INSYS THERAPEUTICS INC, H1 2018

Its lead product candidate Syndros (dronabinol oral solution) is intendedfor the treatment of chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in patients with AIDS.

  • Marijuana
  • Opioid
  • United States
  • World
  • Product Initiative
  • Indication Name
  • OPIUM (OPIOID) ADDICTION - PIPELINE BY OREXIGEN THERAPEUTICS INC

The company' s lead product Contrave is an FDA-approved prescription medicine in the US, for weight loss in obese adults.

  • Opioid
  • Therapy
  • Company
  • Product Initiative
  • Omeros Corporation

Intravenous Tranexamic Acid (IVTA) to Prevent Blood Loss in Joint Replacement Surgery Non-inferiority Trial of Oral Tranexamic Acid Vs.

  • Arthritis
  • Clinical Trial
  • Opioid
  • Pharmaceutical
  • World
  • INNOCOLL AG
  • POST-OPERATIVE PAIN - PIPELINE BY INNOCOLL AG, H1 2019

IN THE MMT MODEL, PAIN BEHAVIOR WAS ANALYZED AS WEIGHT-BEARING ASYMMETRY (I. E.

  • Opioid
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

There were no significant differences in age, gender, race/ ethnicity, PS, or weight loss between BI and BE pts and no differences between BE-Choice and BE-Inappropriate pts.

  • Opioid
  • Research And Development
  • United States
  • Company
  • Company Operations